Asia FX moves little with focus on US-China trade, dollar steadies ahead of CPI
China Pharma Holdings Inc (CPHI) stock has reached a 52-week low, trading at $0.12, with InvestingPro data showing concerning fundamentals including negative EBITDA of -$1.97M and revenue decline of -35.41% over the last twelve months. The company faces a challenging market environment. This latest price level reflects a significant downturn over the past year, with the stock experiencing a 1-year change of -57.69%. Investors are closely monitoring the pharmaceutical company's performance, with InvestingPro analysis revealing high price volatility and weak gross profit margins at -43.84%. The company's current ratio of 0.65 indicates potential liquidity challenges as it navigates through these turbulent times. Market participants remain attentive to any signs of a turnaround that could influence the stock's trajectory. For deeper insights into CPHI's financial health and additional key metrics, check out the full analysis on InvestingPro, which offers 8 more exclusive ProTips.
In other recent news, China Pharma Holdings Inc. has announced a 1-for-10 reverse stock split of its common stock. This corporate action, effective April 15, 2025, was unanimously approved by the Board of Directors and later ratified by stockholders. The reverse stock split will consolidate every 10 shares of the company's issued and outstanding common stock into one share. Shareholders will not receive fractional shares; instead, any fractional entitlements will be rounded up to the nearest whole share. This move is designed to affect all shareholders uniformly, maintaining their percentage interest in the company's outstanding common stock, aside from minor adjustments due to rounding. The Board determined the final split ratio on March 26, 2025. These recent developments reflect China Pharma's strategic decisions to manage its stock structure.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.